Nicola Chapman | White & Case LLP International Law Firm, Global Law Practice

Nicola Chapman

Associate, London

T +44 20 7532 1297

E nicola.chapman@whitecase.com

Overview

Nicola Chapman is an associate in the Firm's Banking Practice in London. Nicola's experience includes advising on a range of domestic and cross-border transactions including acquisition finance and general bank lending acting for private equity sponsors, their portfolio companies, other borrowers and banks.

Prior to joining White & Case in August 2015, Nicola worked in the banking team of a magic circle firm in London. During this time Nicola spent six months on secondment to the capital markets origination team at Citibank and nine months on secondment to the loan markets team at The Royal Bank of Scotland plc, as well as spending six months working in her previous firm’s banking team in Singapore.

Bars and Courts

  • England and Wales

Education

  • LPC, College of Law
  • LLB (Hons), The London School of Economics and Political Science

Languages

  • English

Experience

Refinancing of PLAY, 2017

Advised P4 Sp z. o.o and its shareholders in relation to its PLN 7bn (approximately €1.65 billion) loan and €500m notes refinancing and recapitalisation.

Advent's acquisition of Brammer, 2017

Advised GSO in relation to its financing of Advent's acquisition of Brammer Limited (formerly Brammer plc).

Bridgepoint's acquisition of Zenith, 2017

Advised Bridgepoint on its £425m term loan B financing (and £110m undrawn facilities) for the acquisition of Zenith – the largest ever Sterling unitranche financing.

BC Partner’s acquisition of Keter Group, 2016

Advised in relation to Keter Group's acquisition by BC Partners Ltd and the Public Sector Pension Investment Board of a majority stake in the group from the Sagol family. The transaction is the biggest ever LBO in Israel and has been described as the "deal of the decade" in the Israeli press.

CapVest's acquisition of IBAM and Mallinckrodt Nuclear Imaging, 2016
Advised the lenders in relation to the financing of the IBA Molecular's (a portfolio of CapVest) carve-out acquisition from Mallinckrodt Plc of its global nuclear imaging radiopharmaceuticals division.